Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-antitrypsin - Arriva/Hyland Immuno/Protease Sciences

Next Previous
Drug Profile

Alpha-antitrypsin - Arriva/Hyland Immuno/Protease Sciences

Alternative Names: Alpha-1 antitrypsin - Arriva/Hyland Immuno/Protease Sciences; Alpha-1 proteinase inhibitor - Arriva/Hyland Immuno/Protease Sciences; Inhaled rAAT - Arriva/Hyland Immuno/Protease Sciences; rAAT - Arriva/Hyland Immuno/Protease Sciences

Latest Information Update: 08 Sep 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protease Sciences
  • Developer Arriva Pharmaceuticals; Hyland Immuno
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action HIV protease inhibitors; Leucocyte elastase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency; Cystic fibrosis

Highest Development Phases

  • Discontinued Alpha 1-antitrypsin deficiency; Chronic obstructive pulmonary disease; Cystic fibrosis; HIV infections; Otitis media; Viral hepatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Feb 2008 Phase II development for alpha 1-antitrypsin deficiency is ongoing
  • 31 Oct 2006 Discontinued - Preclinical for Cystic fibrosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top